Future unclear for Impax Parkinson’s drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Impax Laboratories is evaluating options for its Parkinson's disease candidate Vadova (carbidopa/levodopa) after receiving its second "not approvable" letter from FDA, the firm announces Jan. 30. According to the company, "FDA's action is primarily based on unresolved issues relating to product nomenclature and its belief of a likelihood of medication errors resulting from confusion of Vadova with other marketed forms of carbidopa/levodopa." Bristol-Myers Squibb markets a controlled-release carbidopa/levodopa as Sinemet CR. "We will continue to pursue discussions with FDA concerning this decision and we are evaluating all options for the product," Impax CEO Larry Hsu said. The first "not approvable" letter was issued over concerns with clinical pharmacology and chemistry, manufacturing and controls, which Impax said were successfully resolved and were not cited in the second letter...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.